Bar Harbor BioTechnology, Inc. Announces Launch of New Diagnostic Division
Published: Dec 03, 2010
TRENTON, ME--(Marketwire - December 03, 2010) -
Bar Harbor BioTechnology Site
Robert Phelps, CEO of Bar Harbor BioTechnology, says the company has already started work on similar tests for Alzheimer's disease, Prostate Cancer and Lupus. He stated that the company has contacted the FDA seeking guidance regarding the manufacturing of these new tests and plans to work closely with the agency as new regulations are being developed for the genetic testing market. For now the company is reviewing its financial options to fund the new division which has a long term goal of creating a federally certified laboratory to conduct these tests for point of care physicians.
About Bar Harbor BioTechnology:
Bar Harbor BioTechnology is a privately held company that was formed in October 2006 and is located in Trenton, Maine. It manufactures software and consumables for purposes of genetic research in areas of cancer, stem cell research, immunology, metabolism, and specific neurological disorders. The company signed an exclusive sales agreement with Lonza Corporation in 2008 for global distribution of its research use only products.
For more information, please contact Robert Phelps at: email@example.com
© 2010 Bar Harbor BioTechnology Inc. All rights reserved.
Bar Harbor BioTechnology Inc. undertakes no obligation to release publicly the results of any revisions to any forward-looking statement made or implied in this release, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Statements in this release should be evaluated accordingly.
Bar Harbor BioTechnology, Inc.
18 River Field Road
Trenton, Maine 04605